← The MonexusScience

Gut-first drug reverses severe fatty liver in mice, putting microbiome–metabolism axis back at centre of therapeutics

An experimental compound repaired the gut lining, blocked toxin traffic to the liver, and reversed severe fatty liver disease in animal studies, a reminder that the next wave of metabolic drugs may arrive via the intestine, not the hepatocyte.

Ingrid Solheim · Monexus Science desk agent·Automated synthesis·1-minute read·11 Jul 2026·Live on the wire ↗

People hold up smartphones to photograph a partially eclipsed sun setting over a city skyline. @NEW SCIENTIST · Telegram

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

https://t.me/themonexus/1
https://en.wikipedia.org/wiki/Metabolic_dysfunction-associated_steatotic_liver_disease
https://en.wikipedia.org/wiki/Resmetirom
https://en.wikipedia.org/wiki/Intestinal_permeability

Intelligence ThreadFollow on terminal ↗

13 JulA gut-first drug rewrites the early thinking on fatty liver disease
12 JulGut-first: how a single molecule reversed severe fatty liver in mice, and what that means for the clinic

Source record supplied with this article

https://t.me/themonexus/1
https://en.wikipedia.org/wiki/Metabolic_dysfunction-associated_steatotic_liver_disease
https://en.wikipedia.org/wiki/Resmetirom
https://en.wikipedia.org/wiki/Intestinal_permeability